Notice of Proposed Sale · 144
Kestra Medical Technologies, Ltd.
KMTSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- KESTRA MEDICAL TECHNOLOGIES, LTD.
- Issuer CIK
- 0001877184
- SEC file number
- 001-42549
- Phone
- (425) 279-8002
- Person for whose account securities are to be sold
- COHEN RAYMOND W
- Relationships to issuer
- Officer
- Street
- 3933 LAKE WASHINGTON BLVD NE
- Street (continued)
- SUITE 200
- City
- KIRKLAND
- State / country code
- WA
- Postal code
- 98033
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 3,330 | 97,503.90 | 59,561,795 | 09/30/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 225 Liberty Street
- Street (continued)
- Floor 37
- City
- New York
- State / country code
- NY
- Postal code
- 10281
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/04/2026 | Vesting of restricted stock unit awards | KESTRA MEDICAL TECHNOLOGIES, LTD. | 3,330 | N | 09/04/2026 | Granted as part of issuer equity compensation plan |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/30/2026
- Signed
- Raymond Cohen
Company context
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital soluti